Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZNTL 
Zentalis Pharmaceuticals Llc (ZNTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ZNTL (1-star) is a SELL. SELL since 1 days. Profits (-27.61%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $5.86
1 Year Target Price $5.86
| 3 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.39% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.90M USD | Price to earnings Ratio - | 1Y Target Price 6.31 |
Price to earnings Ratio - | 1Y Target Price 6.31 | ||
Volume (30-day avg) - | Beta 1.61 | 52 Weeks Range 1.01 - 5.44 | Updated Date 06/29/2025 |
52 Weeks Range 1.01 - 5.44 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -746.4% |
Management Effectiveness
Return on Assets (TTM) -26.62% | Return on Equity (TTM) -59.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -208898718 | Price to Sales(TTM) 3.16 |
Enterprise Value -208898718 | Price to Sales(TTM) 3.16 | ||
Enterprise Value to Revenue 7.77 | Enterprise Value to EBITDA -2.31 | Shares Outstanding 71951904 | Shares Floating 49780665 |
Shares Outstanding 71951904 | Shares Floating 49780665 | ||
Percent Insiders 13.58 | Percent Institutions 80.34 |
Analyst Ratings
Rating 3.7 | Target Price 5.86 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zentalis Pharmaceuticals Llc
Company Overview
History and Background
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer. Founded in 2014, it has advanced multiple product candidates into clinical development.
Core Business Areas
- Oncology Drug Development: Zentalis focuses on developing small molecule therapeutics for various types of cancer.
- Research and Discovery: The company invests in research to identify new targets and develop novel drug candidates.
- Clinical Trials: Zentalis conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Kimberly Blackwell, MD, serves as CEO. The organizational structure includes research, clinical development, and commercial operations teams.
Top Products and Market Share
Key Offerings
- ZN-c3: A WEE1 inhibitor being developed for advanced solid tumors, including ovarian cancer and other gynecological cancers. No current market share data is available as it is still in clinical trials. Competitors include companies developing other WEE1 inhibitors and standard chemotherapy regimens.
- ZN-d6: An oral selective estrogen receptor degrader (SERD) for estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer. No current market share data is available as it is still in clinical trials. Competitors include AstraZeneca (Fulvestrant) and other oral SERDs in development.
- ZN-a1: A BCL-2 inhibitor for hematologic malignancies. No current market share data is available as it is still in clinical trials. Competitors include AbbVie and Roche (Venclexta).
Market Dynamics
Industry Overview
The oncology drug market is large and competitive, with significant unmet needs. Demand is driven by aging populations and increasing cancer incidence. Innovation focuses on targeted therapies and immunotherapies.
Positioning
Zentalis is positioned as a company focused on developing novel small molecule therapeutics targeting fundamental biological pathways of cancer.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. Zentalis is targeting specific subsets of cancers within this broader market with its drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting validated oncology pathways
- Experienced management team
- Strong preclinical and early clinical data for lead assets
- Proprietary drug discovery platform
Weaknesses
- Clinical stage company with no currently approved products
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
Opportunities
- Potential to address unmet needs in cancer treatment
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through drug discovery efforts
- Positive clinical trial results leading to regulatory approval
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other drug developers
- Patent challenges
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- AZN
- ABBV
- MRK
- BMY
- GILD
Competitive Landscape
Zentalis faces competition from established pharmaceutical companies and other biotechnology companies developing cancer therapies. Its success depends on the differentiation and efficacy of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on the progression of its drug candidates through clinical trials and related investment. Data unavailable without live data access.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates unavailable without live data access.
Recent Initiatives: Recent initiatives include advancing clinical trials for ZN-c3 and ZN-d6 and expanding its research pipeline.
Summary
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on oncology. While it has promising drug candidates and a solid scientific approach, the company faces significant risks related to clinical trial success and competition. Its financial health and market position are dependent on positive clinical outcomes and potential partnerships. The company must carefully manage its cash burn and navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and does not constitute investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zentalis Pharmaceuticals Llc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-03 | CEO, President & Director Ms. Julie M. Eastland M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 166 | Website https://zentalis.com |
Full time employees 166 | Website https://zentalis.com | ||
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.